ATOS - Atossa Genetics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.50
+0.03 (+2.04%)
As of 3:01PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.47
Open1.45
Bid1.46 x 800
Ask1.47 x 1800
Day's Range1.41 - 1.50
52 Week Range1.41 - 19.08
Volume189,222
Avg. Volume236,382
Market Cap7.604M
Beta4.37
PE Ratio (TTM)N/A
EPS (TTM)-6.90
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • ACCESSWIRE5 days ago

    An Interview with Atossa CEO Steven Quay MD, Ph.D. Titled, "What Is Gynecomastia?"

    SAN FRANCISCO, CA / ACCESSWIRE / September 14, 2018 / The Groundwork Forum Podcast aims to bring together leaders from all disciplines all over the world to join its Global Community to consider new perspectives ...

  • GlobeNewswire6 days ago

    Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen

    Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported preliminary results from its Phase 1 dose- escalation study of its proprietary topical Endoxifen in male subjects. Safety: There were no clinically significant safety signals and no clinically significant adverse events in participants receiving topical Endoxifen. “Based on these positive preliminary results, we are advancing our topical Endoxifen into a Phase 2 study to reduce gynecomastia in men starting prostate cancer therapy,” commented Dr. Steven C. Quay, CEO and President. “We anticipate retaining a clinical research organization to manage that study in the fourth quarter 2018.

  • GlobeNewswire7 days ago

    Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT

    Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, will host a conference call on September 13, 2018 at 10 am EDT to discuss preliminary results from its Phase 1 dose-escalation study of its proprietary topical Endoxifen in male subjects. The Phase 1 study was a double-blind, placebo-controlled, repeat dose study of 24 healthy male subjects. Atossa assessed safety, tolerability and the pharmacokinetics of proprietary formulations of topical Endoxifen at varying dose levels over 28 days. Callers should ask to be joined into the Atossa Genetics call.

  • ACCESSWIRE27 days ago

    ''Robust Economy, Resilient Market''

    SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2018 / Vista Partners ("Vista") has published August's FREE Macroeconomic & Investment Monthly Newsletter, "Robust Economy, Resilient Market." ...

  • ACCESSWIRE29 days ago

    "What Is Intraductal Immuno-oncology & CAR-T Cell Therapy?"

    SAN FRANCISCO, CA / ACCESSWIRE / August 21, 2018 / The Groundwork Forum Podcast aims to bring together leaders from all disciplines all over the world to join its Global Community to consider new perspectives ...

  • GlobeNewswirelast month

    Atossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update

    SEATTLE, Aug. 13, 2018-- Atossa Genetics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced ...

  • ACCESSWIRE2 months ago

    The Groundwork Forum Podcast Publishes "An Overview of Breast Cancer Treatment Innovator Atossa Genetics"

    SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2018 / The Groundwork Forum Podcas t aims to bring together leaders from all disciplines all over the world to join its Global Community to consider new perspectives ...

  • GlobeNewswire2 months ago

    Atossa Genetics Contracts with Additional Manufacturer of Endoxifen

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that is has added Alchem Laboratories as a U.S. contract manufacturer to supply Endoxifen.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Mueller Industries, Eros International, Gannett Co., MarketAxess, Atossa Genetics, and McDonald's — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mueller ...

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within NetApp, eBay, The Boeing, HCP, Atossa Genetics, and Anavex Life Sciences — Discovering Underlying Factors of Influence

    NEW YORK, July 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NetApp, ...

  • ACCESSWIRE2 months ago

    Vista Partners Publishes July's Macroeconomic & Investment Newsletter

    SAN FRANCISCO, CA / ACCESSWIRE / July 25, 2018 / Vista Partners ("Vista") has published July's FREE Macroeconomic & Investment Monthly Newsletter, "Economy & Market Maintaining Highs." ...

  • GlobeNewswire2 months ago

    Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it is advancing its intraductal microcatheter immunotherapy program with pre-clinical studies being conducted by Translational Drug Development, LLC (“TD2”). “While there has been recent success treating blood cancers with chimeric antigen receptor therapy (or, CAR-T), there has not been much success using CAR-T to treat solid tumors like breast cancer,” commented Steve Quay, Ph.D., MD, President and CEO of Atossa.

  • GlobeNewswire2 months ago

    Atossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has opened a Phase 2 study of its proprietary oral Endoxifen to treat breast cancer in the “window of opportunity” setting, which is the period between diagnosis of breast cancer and surgery. “Once a patient is diagnosed with breast cancer, there is a window of time, typically a number of weeks, before definitive surgery is performed,” commented Steve Quay, Ph.D., MD, President and CEO of Atossa. “Our goal with this study is to show that our proprietary oral Endoxifen can modify the cancer activity in estrogen-receptor-positive patients during this ‘window of opportunity.' Tamoxifen, the current standard of care, has not been effective in this setting, probably because it can take 50-200 days to reach steady-state of Endoxifen blood levels, while the surgery is usually completed within 30 to 45 days of diagnosis.

  • ACCESSWIRE3 months ago

    ''Strong Economy, Trade Wars & Market Volatility''

    SAN FRANCISCO, CA / ACCESSWIRE / June 27, 2018 / Vista Partners ("Vista") has published June's FREE Macroeconomic & Investment Monthly Newsletter, "Strong Economy, Trade Wars & Market Volatility." ...

  • GlobeNewswire3 months ago

    Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has opened its Phase 2 study of proprietary topical Endoxifen on mammographic breast density, or MBD, reduction. Studies by others have shown that a reduction in MBD reduces the risk of developing breast cancer and may potentially improve the accuracy of mammography in finding cancer.

  • Does Atossa Genetics Inc’s (NASDAQ:ATOS) -89.06% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.3 months ago

    Does Atossa Genetics Inc’s (NASDAQ:ATOS) -89.06% Earnings Drop Reflect A Longer Term Trend?

    When Atossa Genetics Inc (NASDAQ:ATOS) announced its most recent earnings (31 March 2018), I did two things: looked at its past earnings track record, then look at what is happeningRead More...

  • ACCESSWIRE4 months ago

    "The Balancing Act"

    SAN FRANCISCO, CA / ACCESSWIRE / May 31, 2018 / Vista Partners ("Vista") has published May's FREE Macroeconomic & Investment Monthly Newsletter titled "The Balancing Act." Vista's monthly ...

  • When Should You Buy Atossa Genetics Inc (NASDAQ:ATOS)?
    Simply Wall St.4 months ago

    When Should You Buy Atossa Genetics Inc (NASDAQ:ATOS)?

    Atossa Genetics Inc (NASDAQ:ATOS), a medical equipment company based in United States, saw a decent share price growth in the teens level on the NasdaqCM over the last few months.Read More...